{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"26","value":"18"},{"groupId":"OG001","lowerLimit":"18","upperLimit":"37","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"Complete Response (CR) rate is defined as the percentage of participants with CR as assessed by the IRC using IWG criteria (2007 Cheson). CR= Disappearance of all evidence of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).","id":"OG000","title":"Alisertib"},{"description":"Pralatrexate 30 mg/m\\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).","id":"OG001","title":"Pralatrexate, or Romidepsin, or Gemcitabine"}],"paramType":"NUMBER","populationDescription":"Response-evaluable population was defined as participants with peripheral T-cell lymphoma confirmed by an independent hematopathology central review, with measurable disease at baseline, who receive at least 1 dose of alisertib or the comparator drug, and 1 postbaseline response assessment of CR, PR, SD or PD by the independent radiology committee.","reportingStatus":"POSTED","timeFrame":"At the end of every 8 weeks from date of first dose treatment; every 12 weeks after 40 week assessment; at end of treatment visit until PD (approximately 3 years)","title":"Complete Response (CR) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}